Autophagy inhibited Ehrlich ascitic tumor cells apoptosis induced by the nitrostyrene derivative compounds: Relationship with cytosolic calcium mobilization
Nenhuma Miniatura disponível
Data
2012-03-05
Autores
Calgarotto, Andrana Karla
Pereira, Gustavo José da Silva [UNIFESP]
Bechara, Alexandre [UNIFESP]
Paredes-Gamero, Edgar Julian [UNIFESP]
Barbosa, Christiano Marcello Vaz [UNIFESP]
Hirata, Hanako [UNIFESP]
Queiroz, Mary Luci de Souza
Smaili, Soraya Soubhi [UNIFESP]
Bincoletto, Claudia [UNIFESP]
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
Apoptosis induction is often associated with increased autophagy, indicating interplay between these two important cellular events in cell death and survival. in this study, the programmed cell death and autophagy induced by two nitrostyrene derivative compounds (NTS1 and NTS2) was studied using the tumorigenic Ehrlich ascitic tumor (EAT) cells. EAT cells were highly sensitive to NTS1 and NTS2 cytotoxicity in a dose-dependent manner. NTS1 and NTS2 IC50 was less than 15.0 mu M post 12 h incubation. Apoptosis was primarily induced by both compounds, as demonstrated by an increase in Annexin-V positive cells, concurrently with cytochrome c release from mitochondria to cytosol and caspase-3 activation. Although cytosolic Ca2+ mobilization is involved in autophagy as well as apoptosis in response to cellular stress in many cancer cell types, from the two nitrostyrene derivative compounds studied, mainly NTS1 mobilized this ion and disparate autophagy in EAT cells. These results suggest that EAT induced cell death by NTS1 and NTS2 involved a Ca2+-dependent and a Ca2+-independent pathways, respectively. in accordance with these results, the treatment of EAT cells with 3 methyladenine (3-MA), an autophagy inhibitor; significantly increased the number of apoptotic cells after NTS1 treatment, suggesting that pharmacological modulation of autophagy augments the NTS1 efficacy. Thus, we denote the importance of studies involving autophagy and apoptosis during pre-clinical studies of new drugs with anticancer properties. (C) 2011 Elsevier B. V. All rights reserved.
Descrição
Citação
European Journal of Pharmacology. Amsterdam: Elsevier B.V., v. 678, n. 1-3, p. 6-14, 2012.